WO2008051326A3 - Identification of contactins and l1- cams as ligands for the amyloid precursor protein - Google Patents

Identification of contactins and l1- cams as ligands for the amyloid precursor protein Download PDF

Info

Publication number
WO2008051326A3
WO2008051326A3 PCT/US2007/018428 US2007018428W WO2008051326A3 WO 2008051326 A3 WO2008051326 A3 WO 2008051326A3 US 2007018428 W US2007018428 W US 2007018428W WO 2008051326 A3 WO2008051326 A3 WO 2008051326A3
Authority
WO
WIPO (PCT)
Prior art keywords
contactins
cams
ligands
identification
precursor protein
Prior art date
Application number
PCT/US2007/018428
Other languages
French (fr)
Other versions
WO2008051326A2 (en
Inventor
Miriam E Osterfield
John G Flanagan
Original Assignee
Harvard College
Miriam E Osterfield
John G Flanagan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Miriam E Osterfield, John G Flanagan filed Critical Harvard College
Publication of WO2008051326A2 publication Critical patent/WO2008051326A2/en
Publication of WO2008051326A3 publication Critical patent/WO2008051326A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to APP regulation by extracellular binding partners. More specifically, the invention porvides methods and compositions for treating or preventing diseases, such as Alzheimer's disease, mediated by Contactins and/or Ll family of proteins. The invention further provides methods for identifying molecules that modulate the binding and/or processing of APP and other related molecules.
PCT/US2007/018428 2006-08-21 2007-08-21 Identification of contactins and l1- cams as ligands for the amyloid precursor protein WO2008051326A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83911406P 2006-08-21 2006-08-21
US60/839,114 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008051326A2 WO2008051326A2 (en) 2008-05-02
WO2008051326A3 true WO2008051326A3 (en) 2009-04-02

Family

ID=39325090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018428 WO2008051326A2 (en) 2006-08-21 2007-08-21 Identification of contactins and l1- cams as ligands for the amyloid precursor protein

Country Status (1)

Country Link
WO (1) WO2008051326A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
KR101434935B1 (en) 2005-11-30 2014-10-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
JP5475994B2 (en) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
PL2825553T3 (en) * 2012-03-14 2018-12-31 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
JP7088572B2 (en) * 2018-04-05 2022-06-21 ゲノム アンド カンパニー New targets for anti-cancer and immune enhancement
US20210230256A1 (en) * 2018-04-05 2021-07-29 Genome And Company Novel target for anti-cancer and immune-enhancing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027109A1 (en) * 2003-05-06 2005-02-03 Mezo Adam R. Methods for chemically synthesizing immunoglobulin chimeric proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027109A1 (en) * 2003-05-06 2005-02-03 Mezo Adam R. Methods for chemically synthesizing immunoglobulin chimeric proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARETZKY, MOLECULAR AND CELLULAR BIOLOGY, vol. 25, no. 20, 2005, pages 9040 - 9053 *
RUSH, EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 22, 2005, pages 39 - 49 *

Also Published As

Publication number Publication date
WO2008051326A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
MX2009012949A (en) Humanized antibodies which bind to aî² (1-42) globulomer and uses thereof.
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2009133294A3 (en) Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007089548A3 (en) Compounds and methods for modulating protein trafficking
WO2005035551A3 (en) Inhibitors of proteins that bind phosphorylated molecules
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2009048537A3 (en) Humanized antibody
WO2008025020A3 (en) Cd30 binding agents and uses thereof
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
MA32031B1 (en) Processes and compositions using polypeptides from the built-in CClothoff
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2007142542A3 (en) Cationic milk proteins for treating mastitis
UA102867C2 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
TW200630327A (en) Substituted phenylalkanoic acids
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2007084986A3 (en) Compositions and methods for preventing or treating feline chronic kidney disease
WO2010059241A3 (en) Treatment of amyotrophic lateral sclerosis
WO2007132292A3 (en) Therapy for alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837108

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837108

Country of ref document: EP

Kind code of ref document: A2